Navigation Links
Actavis Confirms Early Stage Discussions Regarding Potential Combination with Warner Chilcott plc
Date:5/10/2013

PARSIPPANY, N.J., May 10, 2013 /PRNewswire/ -- Actavis, Inc. (NYSE: ACT), a global specialty pharmaceutical leader, today confirmed that Actavis has entered into early stage discussions with Warner Chilcott plc (Nasdaq: WCRX) regarding a potential combination of the two companies.  Actavis further stated that no agreement has been reached and it does not intend to issue further comment regarding its business development initiatives. 

About Actavis, Inc.Actavis, Inc. (NYSE: ACT) is a global, integrated specialty pharmaceutical company focused on developing, manufacturing and distributing generic, brand and biosimilar products.  The Company has global and U.S. headquarters in Parsippany, New Jersey, USA, and international headquarters in Zug, Switzerland. 

For press release and other company information, visit Actavis' Web site at http://www.actavis.com.

Forward-Looking Statement Statements contained in this press release that refer to Actavis' estimated or anticipated future results or other non-historical facts are forward-looking statements that reflect Actavis' current perspective of existing trends and information as of the date of this release. For instance, any statements in this press release concerning prospects related to Actavis' strategic initiatives, including a potential transaction with Warner Chilcott plc, are forward-looking statements. It is important to note that Actavis' goals and expectations are not predictions of actual performance. Actavis' performance, at times, will differ from its goals and expectations. Actual results may differ materially from Actavis' current expectations depending upon a number of factors affecting Actavis' business. These factors include, among others, the inherent uncertainty associated with pending strategic transactions; the difficulty of predicting the timing and outcome of business and corporate development efforts and activities and risks that such activities may not result in a transaction being consummated; the ability to recognize the anticipated synergies and benefits of any transaction; and such other risks and uncertainties detailed in Actavis' periodic public filings with the Securities and Exchange Commission, including but not limited to Actavis' Annual Report on Form 10-K for the year ended December 31, 2012 and Quarterly Report on Form 10-Q for the period March 31, 2013. Except as expressly required by law, Actavis disclaims any intent or obligation to update these forward-looking statements. CONTACTS: Investors:Lisa DeFrancesco (862) 261-7152Media:Charlie Mayr(862) 261-8030(Logo: http://photos.prnewswire.com/prnh/20130124/NY47381LOGO )


'/>"/>
SOURCE Actavis, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Actavis, Inc. to Present at the Bank of America Merrill Lynch 2013 Health Care Conference
2. Actavis First Quarter 2013 Net Revenue Increases 24% to $1.9 Billion
3. Actavis Acquires Worldwide Rights for Valeants Metronidazole 1.3% Vaginal Gel
4. Actavis, Inc. to Host First Quarter 2013 Earnings Conference Call and Webcast
5. Former Clinton Deputy Solicitor General sheds light on flaws in Federal Trade Commissions case in FTC v. Actavis Inc.
6. Actavis, Inc. to Present at the Barclays 2013 Global Healthcare Conference
7. Actavis, Inc. to Present at the Cowen & Company 33rd Annual Health Care Conference
8. Actavis Full Year 2012 Net Revenue Increases 29% to $5.91 Billion
9. Actavis, Inc. to Present at the RBC Capital Markets Healthcare Conference
10. Actavis, Inc. to Host Fourth Quarter 2012 Earnings Conference Call and Webcast
11. Watson Pharmaceuticals, Inc. is Now Actavis, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... -- Andre, DiMino, CEO of ADM Tronics Unlimited, Inc. (OTCQB: ... and products, commented on ADMT,s third quarter fiscal year ... the Company,s quarterly report on Form 10Q available at ... stated "During the quarter ended December 31, 2016 we ... portion of our engineering efforts into the development of ...
(Date:2/22/2017)... , Feb. 22, 2017 Summary ... infarction partnering deals and agreements entered into by ... full report: http://www.reportlinker.com/p03605670-summary/view-report.html Description The ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
(Date:2/22/2017)... 22, 2017 Summary Provides ... partnering deals and agreements entered into by the ... report: http://www.reportlinker.com/p03605673-summary/view-report.html Description The Global ... understanding and access to partnering deals and agreements ... - Trends in partnering deals ...
Breaking Medicine Technology:
(Date:2/22/2017)... (PRWEB) , ... February 22, 2017 , ... ... its certification exam and eligibility requirements effective with the April 2017 testing period. ... 1995. , “The Care Manager Certified (CMC) exam is periodically re-calibrated to ...
(Date:2/22/2017)... ... February 22, 2017 , ... In a ... skipping doses or not filling a prescription because they could not afford to ... problems getting medications were 30-60%*. At the same time, hospitals, pharmacies, ...
(Date:2/22/2017)... Colorado (PRWEB) , ... February ... ... the availability of their newest advanced absorption cannabidiol (CBD) serum, “NANOCALM 300” ... delivery system®, which provides instant absorption from the mouth into the bloodstream. ...
(Date:2/22/2017)... WV (PRWEB) , ... February 22, 2017 , ... ... awarded a contract to Quality Insights to help small practices in Delaware, New ... Payment Program, established by the Medicare Access and CHIP Reauthorization Act of 2015 ...
(Date:2/22/2017)... ... February 22, 2017 , ... Michael ... new media platform connecting healthcare technology professionals and other key stakeholders with an ... quarterly publication starting on March 1, announced Michael J. Hennessy, Jr., president of ...
Breaking Medicine News(10 mins):